378 related articles for article (PubMed ID: 15459210)
1. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Keller AM; Mennel RG; Georgoulias VA; Nabholtz JM; Erazo A; Lluch A; Vogel CL; Kaufmann M; von Minckwitz G; Henderson IC; Mellars L; Alland L; Tendler C
J Clin Oncol; 2004 Oct; 22(19):3893-901. PubMed ID: 15459210
[TBL] [Abstract][Full Text] [Related]
2. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
[TBL] [Abstract][Full Text] [Related]
3. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.
Addeo R; Faiola V; Guarrasi R; Montella L; Vincenzi B; Capasso E; Cennamo G; Rotundo MS; Tagliaferri P; Caraglia M; Del Prete S
Cancer Chemother Pharmacol; 2008 Jul; 62(2):285-92. PubMed ID: 17922275
[TBL] [Abstract][Full Text] [Related]
4. Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study.
Rau KM; Lin YC; Chen YY; Chen JS; Lee KD; Wang CH; Chang HK
BMC Cancer; 2015 May; 15():423. PubMed ID: 25994543
[TBL] [Abstract][Full Text] [Related]
5. Mitomycin C in combination with vinorelbine in anthracycline- and/or taxane-pretreated patients with metastatic breast cancer.
Schippert C; Warm M; Blohmer JU; du Bois A; Lück HJ
Onkologie; 2012; 35(9):500-4. PubMed ID: 23007147
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer.
Chow LW; Yip AY; Lang BH
Am J Clin Oncol; 2007 Apr; 30(2):133-8. PubMed ID: 17414461
[TBL] [Abstract][Full Text] [Related]
7. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.
Alba E; Ruiz-Borrego M; Margelí M; Rodríguez-Lescure A; Sánchez-Rovira P; Ruiz A; Mel-Lorenzo JR; Ramos-Vázquez M; Ribelles N; Calvo E; Casado A; Márquez A; Vicente D; García-Sáenz JA; Martín M
Breast Cancer Res Treat; 2010 Jul; 122(1):169-76. PubMed ID: 20361253
[TBL] [Abstract][Full Text] [Related]
8. Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy.
Palomo AG; Glogowska I; Sommer H; Malamos N; Kilar E; Vega JM; Torrecillas L; Delozier T; Ettl J; Finek J
Anticancer Res; 2012 Oct; 32(10):4539-45. PubMed ID: 23060583
[TBL] [Abstract][Full Text] [Related]
9. Pegylated liposomal doxorubicin (Caelyx®) and oral vinorelbine in first-line metastatic breast cancer patients previously treated with anthracyclines.
Livi L; Meattini I; Scotti V; De Luca Cardillo C; Galardi A; Iermano C; Sanchez L; Nori J; Mangoni M; Franzese C; Orzalesi L; Bertocci S; Agresti B; Masoni T; Bianchi S; Cataliotti L; Biti G
J Chemother; 2011 Jun; 23(3):158-62. PubMed ID: 21742585
[TBL] [Abstract][Full Text] [Related]
10. Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
Martin M; Campone M; Bondarenko I; Sakaeva D; Krishnamurthy S; Roman L; Lebedeva L; Vedovato JC; Aapro M
Ann Oncol; 2018 May; 29(5):1195-1202. PubMed ID: 29447329
[TBL] [Abstract][Full Text] [Related]
11. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation.
Gebbia V; Mauceri G; Fallica G; Borsellino N; Tirrito ML; Testa A; Varvara F; Colombo A; Ferrera P
Oncology; 2002; 63(1):23-30. PubMed ID: 12187067
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
13. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
Ardavanis A; Mavroudis D; Kalbakis K; Malamos N; Syrigos K; Vamvakas L; Kotsakis A; Kentepozidis N; Kouroussis C; Agelaki S; Georgoulias V;
Cancer Chemother Pharmacol; 2006 Dec; 58(6):742-8. PubMed ID: 16718470
[TBL] [Abstract][Full Text] [Related]
14. Pegylated liposomal doxorubicin (Duomeisu
Jiang H; Li H; Song G; Di L; Shao B; Yan Y; Liu X; Chen Y; Zhang R; Ran R; Liu Y; Gui X; Wang N; Wang H
Breast Cancer Res Treat; 2023 May; 199(1):67-79. PubMed ID: 36877215
[TBL] [Abstract][Full Text] [Related]
15. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study.
Sparano JA; Makhson AN; Semiglazov VF; Tjulandin SA; Balashova OI; Bondarenko IN; Bogdanova NV; Manikhas GM; Oliynychenko GP; Chatikhine VA; Zhuang SH; Xiu L; Yuan Z; Rackoff WR
J Clin Oncol; 2009 Sep; 27(27):4522-9. PubMed ID: 19687336
[TBL] [Abstract][Full Text] [Related]
16. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma.
Zelek L; Barthier S; Riofrio M; Fizazi K; Rixe O; Delord JP; Le Cesne A; Spielmann M
Cancer; 2001 Nov; 92(9):2267-72. PubMed ID: 11745280
[TBL] [Abstract][Full Text] [Related]
17. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
O'Brien ME; Wigler N; Inbar M; Rosso R; Grischke E; Santoro A; Catane R; Kieback DG; Tomczak P; Ackland SP; Orlandi F; Mellars L; Alland L; Tendler C;
Ann Oncol; 2004 Mar; 15(3):440-9. PubMed ID: 14998846
[TBL] [Abstract][Full Text] [Related]
18. A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study.
Vici P; Colucci G; Giotta F; Sergi D; Filippelli G; Perri P; Botti C; Vizza E; Carpino A; Pizzuti L; Latorre A; Giannarelli D; Lopez M; Di Lauro L
J Exp Clin Cancer Res; 2011 Apr; 30(1):39. PubMed ID: 21481280
[TBL] [Abstract][Full Text] [Related]
19. Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor.
Kornek GV; Haider K; Kwasny W; Hejna M; Raderer M; Meghdadi S; Burger D; Schneeweiss B; Depisch D; Scheithauer W
Br J Cancer; 1996 Nov; 74(10):1668-73. PubMed ID: 8932353
[TBL] [Abstract][Full Text] [Related]
20. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
Naumann RW; Coleman RL; Burger RA; Sausville EA; Kutarska E; Ghamande SA; Gabrail NY; Depasquale SE; Nowara E; Gilbert L; Gersh RH; Teneriello MG; Harb WA; Konstantinopoulos PA; Penson RT; Symanowski JT; Lovejoy CD; Leamon CP; Morgenstern DE; Messmann RA
J Clin Oncol; 2013 Dec; 31(35):4400-6. PubMed ID: 24127448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
